
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of ...
Company is advancing portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases Lead candidate JADE-001 on track to enter the clinic in second half of 2025, with initial data expected in first half of 2026 …